Literature DB >> 9038354

The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells.

C Léon1, B Hechler, C Vial, C Leray, J P Cazenave, C Gachet.   

Abstract

The human P2Y1 purinoceptor has been expressed in Jurkat cells and the effects of HPLC purified nucleotides on calcium movements were measured. The most potent agonist was 2-methylthio-ADP followed by ADP. ATP, Sp-ATPalphaS and beta,gamma-methylene-ATP were competitive antagonists. Suramin and PPADS inhibited the effects of ADP. This pharmacological profile is the same as that of the so-called P2T purinoceptor responsible for platelet aggregation, which has not yet been identified. Using PCR we found the P2Y1 receptor to be present in blood platelets and megakaryoblastic cell lines. These data suggest that the P2Y1 receptor may be the elusive P2T receptor.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9038354     DOI： 10.1016/s0014-5793(97)00022-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  54 in total

1.  Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells.

Authors:  R Janssens; J M Boeynaems
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets.

Authors:  H S Park; S M Hourani
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

3.  More pieces of the platelet activation puzzle slide into place.

Authors:  L F Brass
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

4.  Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors.

Authors:  S Honda; Y Sasaki; K Ohsawa; Y Imai; Y Nakamura; K Inoue; S Kohsaka
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

5.  Inhibition of adenylyl cyclase by neuronal P2Y receptors.

Authors:  Ursula Unterberger; Eugenia Moskvina; Thomas Scholze; Michael Freissmuth; Stefan Boehm
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

6.  The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.

Authors:  Susanne Horner; Kirsten Menke; Caren Hildebrandt; Matthias U Kassack; Peter Nickel; Heiko Ullmann; Martyn P Mahaut-Smith; Günter Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-09-13       Impact factor: 3.000

7.  [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors.

Authors:  Dayle Houston; Michihiro Ohno; Robert A Nicholas; Kenneth A Jacobson; T Kendall Harden
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 8.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 9.  P2 receptor subtypes in the cardiovascular system.

Authors:  S P Kunapuli; J L Daniel
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

10.  Historical perspective on ADP-induced platelet activation.

Authors:  Marian A Packham; Margaret L Rand
Journal:  Purinergic Signal       Date:  2011-04-02       Impact factor: 3.765
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.